First-In-Human Data of ALLO-501A, An Allogeneic Chimeric Antigen Receptor (CAR) T Cell Therapy, and ALLO-647 in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL): ALPHA2 Study